JB Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 11, 2026, titled "Press Release".
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
JB Chemicals reported Q4 FY26 revenue of Rs. 904 crores, down 5% YoY from Rs. 949 crores, impacted by post-acquisition integration activities including distribution network optimisation, discontinuation of low-margin trade generics, and alignment of practices with parent entity. Q4 PAT declined 30% to Rs. 101 crores (adjusted PAT at Rs. 150 crores after excluding one-offs and ESOP costs of Rs. 38 crores). Gross margin improved to 70% (vs 66% in Q4 FY25) and EBITDA margin expanded to 27% (vs 25% YoY) due to cost synergies and improved business mix. India business grew 2% in Q4 but 9% for full year; International formulations declined 9% in Q4 due to inventory rationalisation and shipment delays. FY26 full-year revenue grew 6% to Rs. 4,148 crores with PAT up 8% to Rs. 709 crores.
Q4 performance was impacted by one-off integration costs and timing issues, but margin improvement signals successful cost synergy execution. The company expects recovery to begin from Q1 FY27 as integration normalises.